^Morgan DE, Spann JS, Lockhart ME, Winningham B, Bolus DN (April 2011). "Assessment of adverse reaction rates during gadoteridol-enhanced MR imaging in 28,078 patients". Radiology. 259 (1): 109–16. doi:10.1148/radiol.10100906. PMID21248237. Specifically, the rate of nausea (0.530%) was less than half the rate (1.4%) in clinical trials of 1251 patients, leading to FDA approval in 1992.